Stockguru.com: Stocks to Watch for December 3, 2008 - SCLX, VSUL, BZYR, ALYI, GLOB, and CYXN

Dec 03, 2008 (M2 PRESSWIRE via COMTEX) -- VSULE | Quote | Chart | News | PowerRating -- Our Stocks to Watch today include : Sino Clean Energy Inc. (OTCBB: SCLX), Visualant Inc. (OTCBB: VSUL), Burzynski Research Institute (OTCBB: BZYR), Alternet Systems Inc. (OTCBB: ALYI), Global Med Technologies Inc. (OTCBB: GLOB), and China Yongxin Pharmaceuticals, Inc. (OTCBB: CYXN)

Visit: http://www.stockguru.com to register for our daily Stocks to Watch and Trade Alerts.

Sino Clean Energy Inc. (OTCBB: SCLX | Quote | Chart | News | PowerRating) Shares stayed steady at $0.23

Sino Clean Energy is a U.S. publicly traded company and a China-based producer and distributor of coal-water mixture ("CWM"). Based in Xi'an Province, Sino Clean Energy is the largest CWM producer in Northwestern China.

SCLX News Yesterday, Sino Clean Energy announced its financial results for the third quarter ended September 30, 2008. For the third quarter of 2008, total revenue increased 1,357.5% to $3.4 million from $0.2 million a year ago. The Company's CWM production facility became operational and CWM production commenced in August of 2007 and since then has increased its production volume to meet demands, reflecting the revenue increase year over year. "We are very pleased with our third quarter results," commented Mr. Baowen Ren, Chairman and Chief Executive Officer of Sino Clean Energy. "We expect strong revenue growth to continue in the fourth quarter with the onsets of the winter months." Gross profit during the quarter increased 2,015.3% to $1.1 million, or 32.8% of total sales, from $0.05 million, or 22.6% of total sales, the prior year. The increase in gross margin was attributed to better control of production overhead and improved production efficiency.

Visualant Inc. (OTCBB: VSUL | Quote | Chart | News | PowerRating) Shares traded down 47.62% at $0.055

Visualant Incorporated, a development stage company, engages in the business of commercializing products and services based on its spectral signature technology. It holds patent applications pertain to the use of controlled illumination with specific bands of electromagnetic radiation, detection of returned electromagnetic radiation, and data management in a manner enabling its devices to establish a unique spectral signature for both individual and classes of items. This unique spectral signature data could be used in various application areas, such as brand protection, forgery detection, homeland security, medical diagnostics, quality control, fluids monitoring, and metal stress analysis. The company was founded in 1998 as Cigar King Corporation and changed its name to Starberrys Corporation in 2002. Further, it changed its name to Visualant Incorporated in 2004. Visualant is based in Seattle, Washington.

VSUL News Yesterday, Visualant announced the conversion of $906,822.68 of outstanding debt into restricted shares of the company common stock at a price of $0.15 per share. Visualant Chairman, Ron Erickson, said, "In a difficult economic climate, the conversion of our debt holders into Visualant stock exhibits a solid commitment to, and belief in the Company's technology and future business opportunities." The debt conversion will add 6,039,010 additional outstanding shares giving the Company a total issued and outstanding of approximately 24,492,901 shares.

Burzynski Research Institute (OTCBB: BZYR | Quote | Chart | News | PowerRating) Shares traded up 33.33% at $0.04

Burzynski Research Institute, Inc. engages in the research, production, marketing, promotion, and sale of medical chemical compounds. Its medical compounds include growth-inhibiting peptides, amino acid derivatives, and organic acids, which are known under the trade name Antineoplastons used in the treatment of human cancer. The company is conducting a range of Phase II clinical studies for the treatment of various cancers using a combination of Antineoplastons A10 and AS2-1. Its clinical trials study the use of Antineoplastons A10 and AS2-1 for treating patients with glioblastoma multiforme, anaplastic astrocytoma, brain tumors, brain stem glioma, primitive neuroectodermal tumors, low grade astrocytoma, anaplastic astrocytoma, mixed glioma, glioblastoma multiforme, primary malignant brain tumors, visual pathway glioma, and malignancies. The company also provides consulting services. Burzynski Research Institute was founded in 1977 and is based in Houston, Texas.

BZYR News Yesterday, The Burzynski Research Institute announced that its antineoplaston A10 and antineoplaston AS2-1 therapy (ANP) has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of gliomas. It is estimated that in 2008 more than 21,000 men and women in the U.S. will be diagnosed with this type of cancer, with prevalence estimated at approximately 84,000 cases. "We are encouraged by the FDA's action. Initially, BRI sought orphan drug designation for ANP in optic pathway glioma in children, a much narrower indication involving a smaller segment of tumors," said Dr. Stanislaw R. Burzynski, M.D., Ph.D. "However, the FDA extended orphan drug designation to all gliomas, a recognition we believe underlies the broad potential of anitneoplaston therapy for the treatment of patients with cancer of the brain and nervous system. There is now even more motivation for us to evaluate our therapy as an innovative and efficacious choice in a treatment spectrum where disease management options are still quite limited."

Alternet Systems Inc. (OTCBB: ALYI | Quote | Chart | News | PowerRating) Shares traded down 12.50% at $0.14

Alternet Systems, Inc. provides telecom, application software, and transactions solutions for government, business, schools, hospitals, and residents. It offers convergent voice and data services over IP networks; education and health-care application software and systems; and electronic transaction platforms for the mass transportation and utility markets primarily located in Latin America, North America, and the Caribbean. In addition, the company develops, markets, and sells Internet application systems and software under the names ?SchoolWeb? and ?HealthWeb?. Alternet Systems, Inc. was founded in 2002 and is based in Vancouver, Canada.

ALYI News Yesterday, Alternet Systems announced that Transtech de Guatemala, S.A., a regional subsidiary of the Company's joint venture with Tianjin IC Card Public Network Systems Co. LTD (TCPS), has signed a $25 million contract with the Municipality of the City of Guatemala for the operation and management of a bus prepaid fare collection system, user information systems, fleet management systems and security systems for the municipality's transportation company Transmetro, Inc. The population that will be served by these systems is estimated at more than 2.5 million passengers per day and more than 630 million trips per year. The initial duration of the contract is for 10 years and it is renewable for another 10 years, exclusively.

Global Med Technologies Inc. (OTCBB: GLOB | Quote | Chart | News | PowerRating) Shares traded down 6.67% at $0.70

Global Med Technologies, Inc. designs, develops, markets, and supports information management software products for blood banks, hospitals, centralized transfusion centers, and other health care related facilities in the United States, Africa, Canada, and the Caribbean. Its products include SafeTrace, which is used to assist community blood centers, hospitals, plasma centers, and outpatient clinics for the collection and management of blood and blood products; SafeTrace Tx, a transfusion management information system designed for hospitals and centralized transfusion centers to enable the quality of blood transfused into patient-recipients; and ElDorado Donor, a blood management software application designed to provide the information system needs of blood banks and donor centers. The company, through its subsidiary, PeopleMed.com, Inc., (PeopleMed) develops a software application designed to provide HMO providers and other third party payers access to clinical information for chronic disease patients. PeopleMed supports chronic disease management as an application service provider and its system uses the Internet to co-ordinate sources of information and users of a patient?s clinical information, including laboratory, pharmacy, primary and specialty care providers, claims, and medical records. Global Med Technologies also involves in licensing software; the provision of maintenance, consulting, and support services; and in the resale of software obtained from vendors. The company was founded in 1989 and is based in Lakewood, Colorado.

GLOB News Yesterday, Global Med Technologies announced that its European subsidiary, Inlog S.A., has licensed its EdgeTrack Transfusion Software, marketed as "Hemo Serveur" in France, to 21 Assistance Publique - Hopitaux de Paris ("AP-HP") hospitals, representing 23,000 patient beds. For Global Med, this project represents over $2 million, at current exchange rates, in software and services.

China Yongxin Pharmaceuticals, Inc. (OTCBB: CYXN | Quote | Chart | News | PowerRating) Shares traded up 4% at $0.065

China Yongxin Pharmaceuticals, Inc. engages in the wholesale distribution of pharmaceutical products, medical products and equipment, herbal and nutritional supplements, and cosmetics to hospitals, clinics, and retail pharmacies primarily in the People?s Republic of China. It also operates drugstores that offer 8,000 different types of products, including its proprietary brand of ginseng-based products, as well as an assortment of other merchandise comprising traditional Chinese medicines, health and natural products, skin care products, and cosmetics. The company involves in the cultivation, processing, manufacture, and distribution of ginseng electuary, pellets, and liquid extracts that are distributed by wholesalers and in retail drugstores. It markets and distributes its ginseng and ginseng by-products under the proprietary Gaoliyuan i(degree)Zinuo, Longlife, and Yongxintang brand names to various pharmaceutical, health supplement, and cosmetic manufacturers and distributors in mainland China, Southeast Asia, Europe, and the United States. China Yongxin Pharmaceuticals, Inc. was formerly known as Nutradyne Group, Inc. and changed its name to China Yongxin Pharmaceuticals, Inc. in May 2008. The company was founded in 1993 and is headquartered in City of Industry, California.

CYXN News Yesterday, China Yongxin Pharmaceuticals announced that it has recently established a Retailing Chain Management Head Office to uniformly manage its growing base of chain drugstores. "We established the Retailing Chain Management Head Office to further the implementation of our 5-year strategic development plan for the retailing chain business of China Yongxin," stated Mr. Yongxin Liu, Chairman and CEO of China Yongxin Pharmaceuticals, Inc. "This facility will allow us to plan for the expansion of the retailing chain through all levels, to integrate our resources and methodically execute on rolling out new stores. Concurrently, it will allow us to set up a standardized medicine retailing chain operation system, to construct a scalable operation that adopts international standards, and enjoys competition in the market. Additionally, the Head Office helps to create the China Yongxin retailing chain brand image with a unique chain operations pattern. So, in effect, this facility will help us to enhance our competitive advantage." He added, "The establishment of the China Yongxin Retailing Chain Management Head Office signals that China Yongxin's retail chain business has entered into a new phase of growth. The implementation of a uniform 'VI' system, a standardized operations handbook, a uniform business management system, and standardized operations regulations provide a strong foundation for rapid enterprise growth and continuous expansion. It will lead our retail drugstore operations in a healthy, stable and continuous development direction."

About StockGuru.com:

StockGuru.com is an investment information web site for smallcap and over-the-counter bulletin board stocks. StockGuru features daily email alerts to members, company profiles, audio interviews of CEO's or other key executives, and company news. Company and financial reports are authored by business analysts. To join our email alert list, please visit: http://www.stockguru.com/index.php?option=com_content&view=article&id=31&Itemid=5

About ShareholderVision.com:

Occasionally companies mentioned are also featured at ShareholderVision.com. This innovative web site featuring company videos of corporate executives and key personnel. All videos are shot in high-definition format and are edited for content purposes.

To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at (469) 252-3031, or you email us at email: john@stockguru.com and we will gladly send you more information on featuring your company with StockGuru.com

Stockguru.com ("SG") provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements.

CONTACT: John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index